Frontiers in Immunology · 2013 · 79 citations · 150 references
Life SciencesImmunologyOncologyCancer ImmunologyInnate ImmunityTumor ImmunologyCancer ImmunotherapyNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell TherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesAntibody-dependent Cell-mediated CytotoxicityAntibody-dependent Cellular CytotoxicityImmune Cell CytotoxicityInnate Immune EffectorsMonoclonal Antibodies In OncologyMultiple Myeloma TherapyNatural Killer Cell Combination TherapyNatural Killer Cell-based Cancer Immunotherapy
Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are thought to contribute to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by directing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous therapeutic mAb have been developed that target distinct cancer-specific cell markers and may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity. These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can potentiate NK cell cytotoxicity through other mechanisms are being used in combination with therapeutic mAb. In this review, we examine the mechanisms employed by several promising agents used in combination therapies that enhance natural or Ab-dependent cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple myeloma.
150
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Marcus E. Raichle · Science · 2023 · 5.9K citations · Full text